- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415591
Auricular Neuromodulation in Veterans With Fibromyalgia
Auricular Neuromodulation in Veterans With Fibromyalgia: A Randomized, Sham-Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND: In the setting of the opioid epidemic, it is crucial to develop and assess non-pharmacologic treatments for pain and understand underlying mechanisms. In the present investigation, the investigators assess a novel non-pharmacologic approach to chronic pain treatment in Veterans suffering from fibromyalgia (a notoriously difficult to treat pain syndrome that affects 5-10 million Americans and disproportionately affects those returning from the Gulf War), utilizing brain imaging as a biomarker and heart rate variability (HRV) to assess a vagal mechanism. Preliminary results from prior VA-funded feasibility study reveal a trend towards improved pain and function with a FDA-approved, non-pharmacologic therapy - auricular percutaneous electrical nerve field stimulation (PENFS) - over standard therapy control for Veterans suffering from fibromyalgia, correlating to altered network connectivity on rs-fcMRI (resting state functional connectivity MRI). PENFS-related improvements continued through 12 weeks following the completion of treatment and correlated to changes in cross-network connectivity, which differed between groups. Based on the preliminary data, the investigators now intend to rigorously assess the treatment effects of PENFS in a large, double-blind, randomized, sham-controlled study.
OBJECTIVE: The proposed Merit, a randomized, sham-controlled trial of auricular PENFS, evaluates the clinical utility of PENFS for fibromyalgia as compared to sham placebo control, acute and longitudinal PENFS-related neural changes visualized on rs-fcMRI and effects of PENFS on HRV as a potential vagal mechanism of pain relief.
HYPOTHESIS: True PENFS results in non-placebo-related short-and long-term pain and physical function improvements that can be correlated with altered connectivity and HRV.
METHODS: For Aim 1, 240 total participants meeting 2016 diagnostic criteria for fibromyalgia (male and female, age 18-60 years old) will be randomized to either true (n=120) or sham (n=120) auricular PENFS.
Neuroimaging data, self-reported pain, and physical function will be assessed at baseline and at 1- and 12- weeks post-treatment to evaluate neural correlates of PENFS-related treatment. Participants who meet study criteria will be randomized to either true or sham PENFS (series of 4, weekly) treatments and assessed for rsfcMRI and functional changes at 1- and 12-weeks post-treatment. Baseline and follow-up rs-fcMRI will be utilized to identify biomarkers of fibromyalgia and PENFS treatment effects for Aim 2 in a subset of 62 participants from Aim 1 who qualify for MRI procedures. Cardiopulmonary data will be simultaneously collected during rs-fcMRI and utilized for the exploratory Aim 3 to evaluate potential PENFS effects on HRV as an outcome measure for vagal effects. In the initial phase preliminary analytical validation will be accomplished in the first 30 participants following IRB approval, hiring and training of staff, and establishment of an image processing pipeline. If initial milestones are met, the rigorous, double-blind, sham-controlled study in a larger group of Veterans will continue. Veterans who are initially assigned to sham placebo PENFS and are not identified as placebo-responders will be offered the opportunity to test the true PENFS device. This study addresses the critical need to clinically evaluate non-pharmacologic therapies for chronic pain.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anna Woodbury, MD
- Phone Number: 6939 (404) 321-6111
- Email: Anna.Woodbury@va.gov
Study Contact Backup
- Name: Anna M Ree, BA
- Phone Number: 202561 (404) 321-6111
- Email: anna.ree@va.gov
Study Locations
-
-
Georgia
-
Decatur, Georgia, United States, 30033-4004
- Atlanta VA Medical and Rehab Center, Decatur, GA
-
Contact:
- Anna Woodbury, MD
- Phone Number: 6939 404-321-6111
- Email: Anna.Woodbury@va.gov
-
Principal Investigator:
- Anna Woodbury, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 20-60 years old (limit set to minimize brain structural changes due to aging).
- Diagnosis of fibromyalgia by the American College of Rheumatology 2016 criteria.71
- Right-handedness, to provide consistency in brain structure and function.
- Pain score of 4 or greater on DVPRS53 in the 3 months prior to enrollment.
- Intact skin in area of PENFS treatment
- For those who elect to participate in the MRI portion, the ability to safely tolerate MRI
Exclusion Criteria:
Exclusion criteria include:
- pregnancy
- history of seizures or neurologic conditions that alter the brain
- claustrophobia
- MRI-incompatible implants, or other conditions incompatible with MRI (only for those who elect to perform MRI)
- history of uncontrolled psychiatric illness
- autoimmune disease that leads to pain
- skin conditions that can increase risk of infection at PENFS site
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: True PENFS
Percutaneous electrical nerve stimulation applied to the ear x 4 over a 4 week period.
The device is placed over the area of the ear and worn home continuously for a 5-day period, during which time it stimulates at a pre-set on/off duty cycle.
At each in-person visit, the device is replaced until the device has been placed 4 times.
The stimulation delivered is below the threshold of sensory perception.
|
FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
Other Names:
|
Sham Comparator: Sham PENFS
A device is placed at the same points for the same amount of time and at the same intervals as the true device.
This device will not deliver electrical stimulation.
|
FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvements in Clinical Pain (DVPRS)
Time Frame: Through study completion, an average of 1 year
|
The investigators will assess whether pain and functional improvements occur with the application of PENFS.
Clinical pain, as measured by the Defense Veterans Pain Rating Scale (DVPRS), will be our primary outcome.
This measure is rated on a scale of 0 to 10, with 0 being "no pain" and 10 being "as bad as it could be, nothing else matters".
Assessments will be administered at baseline, immediately pre- and post-treatment (the device is replaced every 5 days for a total of 4 device applications), 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Improvements in Clinical Pain (Self-reported analgesic consumption)
Time Frame: Through study completion, an average of 1 year
|
The investigators will assess whether pain and functional improvements occur with the application of PENFS.
Changes in clinical pain will also be assessed for this outcomes via self-reported analgesic consumption.
This measure is not rated on a scale - it is self-reported use.
Assessments will be administered at baseline, immediately pre- and post-treatment (the device is replaced every 5 days for a total of 4 device applications), 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rs-fcMRI as a biomarker of treatment response
Time Frame: Baseline, 12 weeks post-treatment
|
Resting state functional connectivity magnetic resonance imaging (rs-fcMRI) will be performed at baseline and 12 weeks post-treatment to assess changes in cross-network connectivity with the default mode network (DMN) and sensorimotor network (SMN) as well as connectivity within the salience network (SN).
|
Baseline, 12 weeks post-treatment
|
PENFS effects on parasympathetic tone as measured by heart rate variability (HRV)
Time Frame: Baseline, 12 weeks post-treatment
|
Heart rate variability (HRV) will be assessed at the MRI scans at baseline and 12 weeks post-treatment with an MR-compatible pulse oximeter to evaluate the effects of PENFS on parasympathetic tone.
|
Baseline, 12 weeks post-treatment
|
Functional Improvements (Arm curls)
Time Frame: Through study completion, an average of 1 year
|
Functional improvements will be assessed using the arm curl test.
Assessments will be administered at baseline, immediate post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Functional Improvements (30-s chair stand)
Time Frame: Through study completion, an average of 1 year
|
Functional improvements will be assessed using the 30-s chair stand.
Assessments will be administered at baseline, immediate post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Changes in Fibromyalgia Severity (FIQ-R)
Time Frame: Through study completion, an average of 1 year
|
Fibromyalgia severity will be assessed via the Fibromyalgia Impact Questionnaire (FIQ-R).
Each question is rated on a scale of 1 to 10 with 1 being the least impact/severity and 10 being the most impact/severity.
Assessments will be administered at baseline, immediate post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Changes in Fibromyalgia Severity (PSD)
Time Frame: Through study completion, an average of 1 year
|
Fibromyalgia severity will be assessed via the Polysymptomatic Distress Scale (PSD).
This measure ranges from scores of 0 to 31, with 0 being the least severe and 31 being the most severe.
Assessments will be administered at baseline, immediate post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Functional Improvements (PROMIS change)
Time Frame: Through study completion, an average of 1 year
|
Functional improvements will be assessed using the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) measures ("physical function," "anxiety," "depression," "fatigue," "sleep disturbance," "social function," "pain interference," "global health").
PROMIS measures are rated on a scale of 1 to 5 with 1 being the least intense ("Never") and 5 being the most intense ("Always").
There are a few questions (i.e.
PROMIS "global health" measure, item 07r) rated on different scales, such as from 1 to 10, with 1 being the least intense and 10 being the most intense.
Assessments will be administered at baseline, immediate post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anna Woodbury, MD, Atlanta VA Medical and Rehab Center, Decatur, GA
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F5050-R
- I01RX005050 (Other Grant/Funding Number: VA RR&D)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Percutaneous electrical nerve field stimulation
-
Children's Hospital of Orange CountyInnovative Health SolutionsRecruitingCOVID-19 | Post-Concussion Syndrome | COVID Long-HaulUnited States
-
Medical College of WisconsinUniversity College, London; Indiana UniversityRecruitingFunctional Gastrointestinal Disorders | Postural Orthostatic Tachycardia Syndrome | Hypermobile Ehlers-Danlos Syndrome | Autonomic Nervous System Disease | Autonomic Nervous System ImbalanceUnited States
-
Medical College of WisconsinChildren's Wisconsin; Advancing a Healthier Wisconsin Endowment (AHW)RecruitingParoxysmal Sympathetic HyperactivityUnited States
-
César Fernández-de-las-PeñasCompleted
-
EMKinetics, IncTerminated
-
InventramKoç UniversityCompletedParkinson DiseaseTurkey
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedFunctional Gastrointestinal DisordersUnited States
-
University of California, Los AngelesInnovative Health SolutionsRecruitingIrritable Bowel Syndrome | Abdominal Pain | Autonomic Nervous System ImbalanceUnited States
-
Universidad Rey Juan CarlosRecruitingNeuropathic Pain | Peripheral Neuropathy | Percutaneous Electrical Nerve StimulationSpain
-
Medical College of WisconsinWithdrawn